stock.name

Intellia Therapeutics Inc

NTLA

Market Cap$2.55B
Close$

Compare Intellia Therapeutics

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Intellia Therapeutics IncIntellia Therapeutics Inc-5.50%-45%--
marketMarket Avg49.51.28%13%6.20.1
HealthcareHealthcare Avg31.91.26%18%7.50.9
$29.35

Current Fair Value

8% upside

Undervalued by 8% based on the discounted cash flow analysis.

Share Statistics

Market cap$2.55 Billion
Enterprise Value$1.69 Billion
Dividend Yield$0.0 (0.0%)
Earnings per Share$-5.35
Beta2.08
Outstanding Shares89,554,891
Avg 30 Day Volume1,592,390

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio-5.51
PEG-69.4
Price to Sales-
Price to Book Ratio2.47
Enterprise Value to Revenue32.74
Enterprise Value to EBIT-3.39
Enterprise Value to Net Income-4
Total Debt to Enterprise0
Debt to Equity0

Revenue Sources

No data

ESG Score

No data

About Intellia Therapeutics Inc

211 employees
CEO: John Leonard

Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron. Intellia Th...